WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer
Status:
Terminated
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label, pilot study in patients with a diagnosis of recurrent ovarian,
fallopian tube or primary peritoneal carcinoma who have undergone standard cytoreductive
surgery following by adjuvant chemotherapy. It is expected that this first surgery was
optimal - as defined as no residual tumor > or = 1 centimeter. Patient has clinical evidence
of a first recurrence. The patient undergoes surgery and isotonic normal saline (perfusate)
heated and administered into the abdomen, followed by hyperthermic intraperitoneal
chemotherapy infusion (HIPC) administering carboplatin (chemotherapy). Six weeks after
surgery patients will receive adjuvant chemotherapy with Paclitaxel and Carboplatin for 6
cycles.